Avaliação de Transtornos de Depressão e Ansiedade e Correlação com o Tratamento de Pacientes com Psoríase Vulgar by Kamilly Leitão Pitman Machado, Adriana et al.
321
Artigo Original
Avaliação de Transtornos de Depressão e Ansiedade 
e Correlação com o Tratamento de Pacientes com 
Psoríase Vulgar      
Adriana Kamilly Leitão Pitman Machado1, MD, MSc; Caio Vinicius Botelho Brito1, MD, MSc; João Augusto Gomes de Souza  
Monteiro de Brito1, MD; Carla Andrea Avelar Pires1, MD, PhD; Francisca Regina Oliveira Carneiro1, MD, PhD 
1Center of Biological and Health Sciences, State University of Pará, Belém, Pará, Brazil
RESUMO – Introdução: A psoríase é uma doença crónica inflamatória multissistêmica com diversas comorbidades, entre elas 
estão os transtornos de ansiedade e de depressão. Metodologia: Avaliar a prevalência de ansiedade e depressão, respectiva-
mente pelos questionários GAD-7 and PHQ-9 em relação com variáveis socio-demográficas e formas de tratamento. Resultados: 
Foram avaliados 90 pacientes (56 do género feminino), 41 pacientes (45,56%) utilizavam apenas tratamento tópico, 28 pacien-
tes (31,11%) utilizavam metotrexato via oral e 21 (23,33%) utilizavam imunobiológicos (agentes anti-TNF-alfa). Observou-se que 
47 pacientes dos avaliados (52,23%) apresentaram algum grau de depressão (leve, moderado ou severo) e que 53 pacientes 
(58,89%) apresentaram algum grau de transtorno de ansiedade (leve, moderado ou severo). Não houve relação estatística signifi-
cante entre o quadro de ansiedade e de depressão e o score PASI, assim como a faixa etária, a empregabilidade ou a escolarida-
de. Houve associação estatística entre o quadro psiquiátrico e o género feminino (p<0,0001) e menor prevalência de depressão 
(p=0,0336) com o uso de imunobiológicos. Conclusão: Os achados ratificam os achados encontrados na literatura, nos quais o 
quadro psiquiátrico possui também uma ampla associação com a fisiopatogenia inflamatória da psoríase, em especial em relação 
ao TNF-alfa, de modo que terapias anti-TNF possam vir a ser uma alternativa para o tratamento de depressão ou de transtornos 
de ansiedade associados à psoríase. 
PALAVRAS-CHAVE – Ansiedade; Depressão; Perturbações Ansiosas; Perturbações Depressivas; Psoríase/complicações; Psoríase/
psicologia.
Evaluation of Depression and Anxiety Disorders 
and Correlation with the Treatment of Patients with 
Psoriasis Vulgaris 
ABSTRACT – Introduction: Psoriasis is a chronic inflammatory multisystemic disease with several comorbidities, namely anxiety 
and depression disorders. Methods: In this study, the prevalence of these psychiatric entities was investigated by the PHQ-9 and 
GAD-7 questionnaries and related to the socio-demographic variables and to the forms of clinical treatment. Results: A total of 
90 patients (56 females) were analyzed. Of these, 41 patients (45.56%) used topical treatment only, 28 patients (31.11%) used 
oral methotrexate and 21 patients (23.33%) used immunobiological agents (anti-TNF-alfa agents). It was observed that 47 patients 
(52.23%) presented some degree of depression (mild, moderate or severe) and 53 patients (58.89%) presented some degree of 
anxiety disorder (mild, moderate or severe). There was no statistical relationship between the anxiety and depression scores and 
the PASI score, as well as age, employability or schooling. There was a statistical association between psychiatric comorbidities 
and the female gender (p <0.0001). It was also observed a lower prevalence of depression (p = 0.0336) on patients using 
immunobiological treatments. Conclusion: The findings confirm published data, showing association of psychiatric conditions with 
psoriasis, especially in relation to TNF-alpha, so that anti-TNF therapies may become an alternative for the treatment of depression 
or anxiety disorders associated with psoriasis.  
KEYWORDS – Anxiety; Anxiety Disorders; Depression; Depressive Disorder; Psoriasis/complications; Psoriasis/psychology.
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Psoriasis is a chronic, immunoinflammatory, cutaneous 
disease characterized by epidermal hyperplasia, accelerated 
keratinocyte evolutionary cycle, and inappropriate immune 
activation. Its distribution is universal with similar involvement 
between the sexes. It has two incidence peaks: between 20 
and 30 years of age and after 50 years.1
This condition affects approximately 2% of the population. 
Its clinical presentation is varied, but psoriasis vulgaris occurs 
in 85% to 90% of patients with the disease. These have a high 
frequency of comorbidities, as well as a significant impact on 
health-related quality of life due to skin appearance and ad-
verse effects of medications.2
Although psoriasis is classically linked to the development 
of cutaneous erythematous desquamative plaques, increasing 
evidence supports its recognition as a multisystem chronic in-
flammatory disease with multiple associated comorbidities, 
such as metabolic syndrome, cardiovascular and cerebral di-
sease, psychosocial effects, alcohol abuse, psychiatric disor-
ders.3-5  
The great impact of psoriasis on the patient's quality of life 
is evident in the aspects of physical and mental health simi-
lar to other diseases such as cancer, arthritis, coronary artery 
disease, and diabetes.6,7 These patients show higher rates of 
depression, anxiety and suicidal ideations as well as alcohol 
abuse, smoking and sexual dysfunction, which are often unre-
cognized or ignored. These comorbidities are more prevalent 
in female patients with severe disease, associated psoriatic ar-
thritis, and previous psychiatric illness.8-10
A significant association was found specifically between 
major depressive disorders and psoriasis, primarily related to 
immune mechanisms and the action of inflammatory cytoki-
nes such as tumor necrosis factor (TNF)-alfa, interleukin-1 (IL-
1), IL-2, IL- 10, IL-6, IL-8, prostaglandin E2 and C-reactive 
protein.11 In particular, TNF-alfa has been identified as a 
proinflammatory cytokine that induces depression even in pa-
tients with no history of mental illness. In addition, its highest 
blood levels were found in patients with suicidal ideations.12
Anti-TNF drugs, such as adalimumab, etanercept and infli-
ximab, used for the treatment of psoriasis have been associa-
ted also with the improvement of psychiatric comorbidities.12 It 
is difficult, however, to ascertain whether the beneficial effect 
observed from the use of anti-TNF drugs is due to a direct 
effect into the pathophysiology of depression or secondary to 
improvement of the cutaneous and joint lesions and conse-
quent improvement of the quality of life.
The dermatologist should always evaluate the social, emo-
tional and psychological aspects when managing patients 
with psoriasis. If these items are addressed in patient care, 
quality of life, prognosis and therapeutic response may be 
improved.13 Therefore, this study aims to determine the pre-
valence of anxiety and depression disorders in patients with 
psoriasis vulgaris diagnosed in the Dermatology outpatient 
clinic of State University of Pará, Brazil, as well as to explore 
their relationship with disease severity, treatment options and 
clinical response to treatment. 
MATERIAL AND METHODS
Observational and cross-sectional study with a quan-
titative approach, performed in a dermatology outpatient 
clinic. The occurrence of depression and anxiety disorders 
in patients diagnosed with psoriasis vulgaris was analyzed. 
Data collection took place after approval of the project by 
the Marco Health Center School from the State Universi-
ty of Para, Brazil Ethics and Research Committee (opinion 
number: 2 451 002, approved on December, 2017) in 
compliance with the guidelines on human research of the 
Helsinki Declaration and the National Health Council Re-
solution 466/2012.
The aim was to apply internationally validated scores 
to patients diagnosed with psoriasis vulgaris, namely ques-
tionnaires such as GAD-7 and PHQ-9 for screening of an-
xiety and depression disorders that were administered in a 
single moment. 
The PHQ-9 score is an internationally validated ins-
trument containing nine questions that allows screening, 
measuring the severity and monitoring depressive disor-
ders. Scores greater than 10 have a sensitivity and spe-
cificity of 88% for major depression. Scores above 5, 10 
and 15 represent mild, moderate and severe conditions, 
respectively.14,15 
The GAD-7 score consists of seven questions. It is va-
lidated and has proven efficiency for screening and moni-
toring the severity of signs and symptoms of generalized 
anxiety disorder. It has a sensitivity of 89% and a specificity 
of 82%. As in PHQ-9, scores above 5, 10 and 15 also 
represent mild, moderate and severe conditions, respec-
tively.16
PASI was calculated and patients were evaluated accor-
ding to disease duration and the therapy: topical, metho-
trexate or immunobiological treatment.
This is a convenience-sampled study, which included all 
consecutive patients who attended to the dermatology ou-
tpatient clinic after the beginning of the research, of both 
sexes, over 18 years, with confirmed clinical diagnosis of 
psoriasis vulgaris and who agreed to participate in the re-
search by signing the informed consent form.
The sample characterization information was obtained 
from a database prepared using Microsoft® Office Excel® 
2013 software. The sample was evaluated by descriptive 
statistics, through frequency distributions (absolute and 
relative), measures of central tendency (arithmetic mean) 
and variance (standard deviation). To assess the overall 
distribution of the sample, the chi-square test of adherence 
was used. For the evaluation of distribution between groups 
(gender, employment status and education), the chi-square 
independence test or the G test were used. To evaluate 
quantitative variables between groups, Student's t-test or 
Mann-Whitney test (for two groups) and one-way ANOVA 
or Kruskall-Wallis (for more than two groups) were used.
All statistical inference was performed using the softwa-
re BioEstat and Graphpad Prism 6, considering significant 
a p-value ≤ 0.05.
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Ninety patients with the diagnosis of psoriasis vulgaris 
were included. There was a predominance of female pa-
tients with 56 women (62.2%) and the predominance of the 
age group of 51 to 60 years in 52.2% of participants. Most 
patients had a high education level (mostly high school), 
were employed and non-users of alcohol or tobacco (Table 
1). 
Disease duration varied between 2 months and 67 
years (mean: 11.59 +/- 8,11). PASI score was below 10 
in 68 patients (75%) at the time of the survey and 22 pa-
tients (24.44%) had a PASI above 10. Out of the 90 pa-
tients enrolled, 41 (45.56%) used only topical treatment, 
28 (31.11%) used oral methotrexate and 21 (23.33%) used 
immunobiological agents (Table 2). Among those who used 
immunobiological agents, 100% used an anti-TNF drug, ei-
ther adalimumab or etanercept.
Tables 2 and 3 demonstrate that there was no statistically 
significant association between the clinical characteristics 
(disease duration, medication in use and time on treatment) 
and, respectively, gender and schooling of the patients.
Furthermore, the prevalence of depression and anxie-
ty was verified according to the PHQ9 and GAD7 questio-
nnaires. Regarding the PHQ9 score, 47 patients (52.23%) 
had some degree of depression, 14 (15.55%) of them had 
mild depression, 15 (16.66%) moderate and 18 (20%) se-
vere. Regarding the GAD7 score, 53 patients (58.89%) had 
some degree of anxiety disorder, 18 (20%) of them had mild 
symptoms, 17 (18.88%) moderate and 18 (20%) severe.  
Eighty six patients (95.56%) out of the 90 studied were 
not treated with any drugs intended for depressive or anxio-
lytic disorders. The prevalence of suicidal thoughts in pa-
tients with Psoriasis in this clinic was 13.33 % among the 90 
patients studied.
Statistically significant association was found between 
the prevalence of depression and anxiety and the female 
gender, a fact that is not correlated with the PASI score. 
The tests for association between qualitative variables - 
Chi-square and G Test - demonstrated that there was no 
statistically significant association (p > 0.05 in all situations) 
between the prevalence of anxiety and depression and em-
ployability or the academic education of patients. In addi-
tion, the categorization of the age group in relation to the 
presence or absence of depression and anxiety demonstra-
ted that no group had statistical strength either. There was 
no statistically significant correlation between the PASI score 
and the presence of depression (p = 0.4868) or anxiety (p 
= 0.2122) (Fig. 1). 
We found a significantly lower prevalence of depression 
in patients using immunobiological agents (p=0.0336).  De-
pression was observed in 6 out of 21 patients treated with im-
munobiological agents (28.6%) whereas it occurred in 15 out 
of 28 (63.6%) and 26 out of 41 (63.4%) under methotrexate 
or topical drugs, respectively (Table 4). 
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Table 1 - Demographics of the group of patients 
with psoriasis vulgaris.   
Demographics n % p-value
Sex
Male 34 37.78 Chi-square
Female 56 62.22 0.0269
Total 90 100.00
Age
18 to 30 years 7 7.78 Chi-square
31 to 40 years 14 15.56 <0.0001
51 to 60 years 47 52.22
>60 years 22 24.44
Total 90 100.00
Schooling
Elementary school 28 31.11 Chi-square
High school 42 46.67 0.0160
University education 20 22.22
Total 90 100.00
Employed
Yes 60 66.67 Chi-square
No 30 33.33 0.0022
Total 90 100.00
Smoking
Yes 4 4.44 Chi-square
No 86 95.56 <0.0001
Total 90 100.00
Alcohol
Yes 10 11.11 Chi-square
No 80 88.89 <0.0001
Total 90 100.00
Figure 1 - PASI score did not correlated with the presence of de-
pression (p = 0.4868, T Test) or anxiety disorders (p = 0.7544, T Test) 




The association between psoriasis and mental health as-
pects is already well established due to social stigmas and chro-
nicity of the disease.17 Feelings of rejection, guilt and shame 
are the main aspects of stigmatization, correlated with the in-
tensity of pruritus, stress, depressive symptoms and quality of 
life.18 Although psoriasis is associated with alcohol drinking 
and smoking habits, in this study no association was found.19
A recent systematic review has shown that psoriasis pa-
tients have a higher risk of anxiety symptoms (approximate-
ly 82.8%), generalized anxiety disorder (33%) and depressive 
symptoms (68%). Other psychiatric symptoms such as sleep 
disorders, sexual dysfunction, and personality disorders are 
also frequently reported. The prevalence of suicidal ideation in 
psoriasis is between 2.4% - 9.7% and commonly occurs in the 
context of depression.20 These data are in agreement with the 
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Table 2 - Clinical characteristics of the whole group of patients with psoriasis vulgaris in a Dermatology  




n % p-value n % n %
Disease duration
<1 year 7 7.78 Chi-square 4 11.76 3 5.36 G Test
1 to 5 years 33 36.67 0.0005 9 26.47 24 42.86 0.1351
6 to 10 years 21 23.33 6 17.65 15 26.78
>10 years 29 32.22 15 44.12 14 25.00
Total 90 100.00 34 100.00 56 100.00
Medication in use
Immunobiological 21 23.33 Chi-square 12 35.30 9 16.07 Chi-square
Methotrexate 28 31.11 0.0323 11 32.35 17 30.36 0.0650
Topic 41 45.56 11 32.35 30 53.57
Total 90 100.00 34 100.00 56 100.00
Time on treatment 
1 to 12 months 14 28.57 Chi-square 8 34.79 6 23.08 Chi-square
13 to 24 months 12 24.49 0.1222 3 13.04 9 34.61 0.2062
>24 months 23 46.94 12 52.17 11 42.31
Total 49 100.00 23 100.00 26 100.00
PASI
0 to 10 68 75.56 Chi-square 23 67.65 45 80.36 Chi-square
>10 22 24.44 <0.001 11 32.35 11 19.64 0.2681
Table 3 - Clinical characteristics according to the schooling of patients with psoriasis vulgaris in a  
Dermatology Clinic.  
Clinical characteristics
Elementary School High school University education
p-value
n % n % n %
Time with the disease
<1 year 2 7.14 4 9.52 1 5.00 G Test
1 to 5 years 12 42.86 13 30.95 8 40.00 0.5053
6 to 10 years 9 32.14 9 21.43 3 15.00
>10 years 5 17.86 16 38.10 8 40.00
Total 28 100.00 42 100.00 20 100.00
Medication in use
Immunobiological 7 25.00 9 21.43 5 25.00 G Test
Methotrexate 7 25.00 13 30.95 8 40.00 0.8121
Topic 14 50.00 20 47.62 7 35.00
Total 28 100.00 42 100.00 20 100.00
Time on treatment 
1 to 12 months 2 14.28 7 31.82 5 38.46 G Test
13 to 24 months 5 35.72 4 9.52 3 23.08 0.5843
>24 months 7 50.00 11 58.66 5 38.46
Total 14 100.00 22 100.00 13 100.00
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results found in this study, with the prevalence of anxiety and 
depression of 58.89% and 52.23%, respectively, and with the 
percent of the patients with suicidal ideations (13%). 
Although anxiety and depression disorders are classically 
related to the severity of psoriasis, both ours and other studies 
showed that there is no relationship between the severity of 
the clinical picture evaluated by the PASI and the occurren-
ce of these psychiatric comorbidities.12 In agreement with the 
findings of this research, in which there was no statistically 
significant relationship between the presence of anxiety and 
depression and the variables such as age, unemployment, 
education and even with PASI values above 10, all patients 
may have a similar risk and should be screened for signs and 
symptoms of depression and anxious mood.12 Strober et al in 
201821 reported the association of depressive symptoms with 
a low educational level, which was not observed in this study. 
In addition, the author describes no gender difference, which 
is contrary to the results of this study, in which females showed 
a higher association with depression and anxiety (Table 5).
Within this investigative scenario, new hypotheses for the 
risk of depression and anxiety were raised. Psoriasis, as a 
chronic and inflammatory disease, has long been interpreted 
as a multisystemic morbidity, not just limited to the skin. It was 
hypothesized that a pathophysiologic mechanism mediated by 
inflammatory cytokines, with special attention to TNF-alpha, 
acts directly in the central nervous system,22 and that targeting 
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Table 4 - Relation of depression and anxiety with medication of the whole group of patients with Psoriasis 




n % n %
Immunobiological 6 12.77 15 34.88 Chi-square
Methotrexate 15 31.91 13 30.24 0.0336
Topic 26 55.32 15 34.88




Yes % No %
Immunobiological 9 16.98 12 32.43 Chi-square
Methotrexate 15 28.30 13 35.14 0.0849
Topic 29 54.72 12 32.43
Total 53 100.00 37 100.00
Table 5 - General assessment of levels of depression and anxiety, use of medication for depression and anxiety 
in patients with psoriasis vulgaris, in the whole group of 90 patients and according to gender.  




n % p-value n % n %
PHQ9 (Depression)
Absent 43 47.77 24 70.60 19 33.92 Chi-square
Mild 14 15.55 4 11.76 10 17.86 0.0078
Moderate 15 16.66 3 8.82 12 21.43
Severe 18 20 3 8.82 15 26.79
Total 90 100.00 34 100.00 56 100.00
GAD7 (anxiety)
Absent 37 41.11 25 73.54 12 21.43 Chi-square
Mild 18 20 4 11.76 14 24.99 <0.0001
Moderate 17 18.88 2 5.88 15 26.79
Severe 18 20 3 8.82 15 26.79
Total 90 100.00 34 100.00 56 100.00
Anxiety and depression medication
Yes 4 4,.44 Chi-square 1 2.94 3 5.36 Chi-square
No 86 95.56 <0.0001 33 97.06 53 94.64 0.0028
Total 90 100.00 34 100.00 56 100.00
Suicidal thoughts
Yes 12 13.33 Chi-square 2 5.88 10 17.86 G Test
No 78 86.66 <0.0001 32 94.12 46 82.14 0.1769
Total 90 100.00 34 100.00 56 100.00
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these cytokines with specific treatment also improves these co-
morbidities.
The PSOLAR Cohort Study, which involved approximately 
12 000 psoriasis patients in 16 different countries receiving 
immunobiological, phototherapy and conventional systemic 
therapies such as methotrexate, acitretin, cyclosporine. and 
corticosteroids,21 demonstrated that treatment with immu-
nobiologicals reduced the risk of depressive symptoms (RR 
0.76; 95% CI 0.59-9.98) compared with conventional syste-
mic therapy (RR 1.05; 95% CI 0.71-1.54). These results are in 
agreement with the data of the present research. In addition, 
the incidence rates of depressive symptoms were significantly 
lower than those in other groups, demonstrating an incidence 
of 3.01 per 100 patient/year (95% CI, 2.73-3.32), 5.85 per 
100 patient/year (95% CI, 4.29-7.97) and 5.70 per 100 pa-
tient/year (95% CI, 4.58-7.10) for biological, phototherapy, 
and conventional therapy, respectively. 
Emerging research suggests that there is a link between 
the pathophysiology of psoriasis and depression. Proinflam-
matory cytokines such as TNF-α and IL-17 are present in both 
psoriasis and depression. Other chronic inflammatory disea-
ses such as systemic lupus erythematosus and Crohn's disease 
are also associated with psychiatric comorbidities, reinforcing 
this link between pathophysiology and opening new horizons 
to the potential of targeted therapies for psoriasis.23,24
Genetic studies provide additional information, as genetic 
polymorphism of TNF-α (rs1799724, a single nucleotide poly-
morphic variation),  which would selectively increase TNF-α 
expression in certain anatomical areas of the cortex, occur in 
depressed patients.25 This highlights that TNF-α may have a 
significant role in the pathogenesis both of psoriasis and of 
depression and as a possible target in the treatment of a cer-
tain group of patients, particularly those who carry this genetic 
polymorphism.
Given the relation between psoriasis and depression, 
the dermatologist will have to be prepared to recognize the 
patient's mental and emotional states and provide a type of 
psychological support to his patient, starting with a highly 
effective doctor-patient relationship, stress management re-
sources and even psychopharmacological and psychological 
therapies. In many cases there will be a need to integrate with 
professionals in Psychology and Psychiatry to address specific 
cases of these specialties.26
CONCLUSION
Psoriasis is a multisystemic chronic disease associated with 
several comorbidities, such as depression and anxiety. Out of 
the 90 psoriasis patients of this study, 52.23% have some de-
gree of depression and 58.89% some degree of anxiety with 
no statistical significance related to education, employability, 
age or PASI score above 10 and only a greater correlation 
with the female gender and a lower prevalence among pa-
tients who are under anti-TNF-alfa treatment.
TNF-α, is pointed as one of the main causes of the inflam-
matory response in the CNS, triggering the neuropsychiatric 
comorbidities, therefore opening doors for using this type of 
immunobiologics in the treatment of psoriasis and these co-
morbidities as a better choice for such patients.
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